University professor, medical doctor, head of department of intensive care and clinical toxicology (1995-2014). Specializes in clinical toxicology, having developed two antidotes used worldwide: fomepizole for toxic alcohol poisoning and hydroxocobalamin for acute cyanide poisoning. Deeply interested in toxicokinetics as well as pharmacokinetics of antidotes. Since 2000, has developed the use of extracorporeal membrane oxygenation in cardiogenic shock induced by cardiotropic toxicants. Now developing a new technology to address the concern of sequestration of drugs in medical devices with extracorporeal circulation, including continuous renal replacement therapy, ECMO, non-specific and specific hemo-adsorption. Since 2018, has developed a new in vitro technology which has been patented. We are presently studying 22 drugs and endogenous substances with sequestration rates ranging from 0 to 100%. We aim to better understand sequestration in order to quickly detect this expected adverse effect, ideally at the pre-clinical phase of drug development, but frequently at the post-marketing phase. More than 250 articles in peer-reviewed journals including NEJM, Lancet, BMJ, Tox Appl Pharmacol, Tox Sci.
University professor, medical doctor, head of department of intensive care and clinical toxicology (1995-2014). Specializes in clinical toxicology, having developed two antidotes used worldwide: fomepizole for toxic alcohol poisoning and hydroxocobalamin for acute cyanide poisoning. Deeply interested in toxicokinetics as well as pharmacokinetics of antidotes. Since 2000, has developed the use of extracorporeal membrane oxygenation in cardiogenic shock induced by cardiotropic toxicants. Now developing a new technology to address the concern of sequestration of drugs in medical devices with extracorporeal circulation, including continuous renal replacement therapy, ECMO, non-specific and specific hemo-adsorption. Since 2018, has developed a new in vitro technology which has been patented. We are presently studying 22 drugs and endogenous substances with sequestration rates ranging from 0 to 100%. We aim to better understand sequestration in order to quickly detect this expected adverse effect, ideally at the pre-clinical phase of drug development, but frequently at the post-marketing phase. More than 250 articles in peer-reviewed journals including NEJM, Lancet, BMJ, Tox Appl Pharmacol, Tox Sci.